Back
Open Access

Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

Session: PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease
Topic: Lipids
Speaker: Professor D. Bhatt (New York, US)
Sponsored by Sanofi US and Regeneron Pharmaceuticals
Event: ESC Congress 2018

Congress Presentation

Add to my library

Like

About the speaker

Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York (United States of America)
44 presentations
8 followers

4 more presentations in this session

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Speaker: Professor D. Bhatt (New York, US)

Access
Slides
Video
Like
Thumbnail

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Speaker: Professor P. Steg (Paris, FR)

Access
Slides
Video
Like
Thumbnail

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

Speaker: Professor J. Jukema (Leiden, NL)

Access
Slides
Video
Like
Thumbnail

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Speaker: Professor D. Bhatt (New York, US)

Access
Slides
Video
Like
Thumbnail

Access the full session

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Speakers: Professor D. Bhatt, Professor D. Bhatt, Professor P. Steg, Professor J. Jukema, Professor D. Bhatt
Access
Like
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources